Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 12/20 | 0.71 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.67 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HTR5A | P47898 | 1/20 | 0.49 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.49 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.49 |
| ▸ | HTR7 | P34969 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10278388 | 0.88 | MAPKAPK2 (0.63) | SIRT1SIRT2MAPKAPK2KDM4EHTR5A | |
| SCHEMBL279185 | 0.84 | SIRT1 (0.53) | SIRT1SIRT2MAPKAPK2KDM4EHTR5A | |
| SCHEMBL7248573 | 0.83 | SIRT1 (0.52) | SIRT1SIRT2MAPKAPK2KDM4EHTR5A | |
| SCHEMBL3484381 | 0.83 | SIRT1 (1.00) | SIRT1SIRT2MAPKAPK2HTR7CYP3A4 | |
| SCHEMBL251128 | 0.81 | SIRT1 (1.00) | SIRT1SIRT2MAPKAPK2SIRT3RECQL | |
| SCHEMBL275312 | 0.81 | SIRT1 (0.52) | SIRT1SIRT2MAPKAPK2KDM4EHTR5A | |
| SCHEMBL274285 | 0.80 | KDM4E (0.54) | SIRT1SIRT2MAPKAPK2KDM4EHTR5A | |
| SCHEMBL8241408 | 0.80 | SIRT1 (0.92) | SIRT1SIRT2MAPKAPK2SIRT3RECQL | |
| SCHEMBL7244005 | 0.78 | SIRT1 (0.47) | SIRT1SIRT2MAPKAPK2KDM4EHTR5A | |
| SCHEMBL28439443 | 0.78 | MAPKAPK2 (0.77) | SIRT1SIRT2MAPKAPK2HTR7CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524704-B2 | Azepinoindole derivatives as pharmaceutical agents | EXELIXIS, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8133992-B2 | Azepinoindole and pyridoindole derivatives as pharmaceutical agents | EXELIXIS, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| EP-1532153-B1 | AZEPINOINDOLE AND PYRIDOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | X CEPTOR THERAPEUTICS INC (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20100173824-A1 | Azepinoindole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2010-07-08 | — | — | US | disclosed |
| US-20090326218-A1 | Azepinoindole and Pyridoindole Derivatives as Pharmaceutical Agents | EXELIXIS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-7595311-B2 | Modulating active of receptors; therapy prevention of disease such aas symthrome X, antidiabetic agents, insulin resistance, hypoglycemic agents | EXELIXIS, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-7485634-B2 | Azepinoindole and pyridoindole derivatives as pharmaceutical agents | EXELIXIS, INC. (US) | 2009-02-03 | — | — | US | disclosed |
| EP-1532153-A1 | AZEPINOINDOLE AND PYRIDOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | X-Ceptor Therapeutics, Inc. (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20050054634-A1 | Modulating active of receptors; therapy prevention of disease such aas symthrome X, antidiabetic agents, insulin resistance, hypoglycemic agents | AKARNA THERAPEUTICS, LTD. (GB) | 2005-03-10 | — | — | US | disclosed |
| US-20040023947-A1 | Azepinoindole and pyridoindole derivatives as pharmaceutical agents | X-CEPTOR THERAPEUTICS INC. | 2004-02-05 | — | — | US | disclosed |
| WO-2003099821-A1 | AZEPINOINDOLE AND PYRIDOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | X-CEPTOR THERAPEUTICS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023947-A1 | Azepinoindole and pyridoindole derivatives as pharmaceutical agents | HTR5A, MTNR1A, PTGDR | SIRT1 2385/4885SIRT2 3154/4885MAPKAPK2 1349/4885 |
| US-20100173824-A1 | Azepinoindole Derivatives As Pharmaceutical Agents | HTR2A, HTR5A, HTR2C | SIRT1 2107/4885SIRT2 2916/4885MAPKAPK2 1457/4885 |
| US-20090326218-A1 | Azepinoindole and Pyridoindole Derivatives as Pharmaceutical Agents | HTR5A, MTNR1A, PTGDR | SIRT1 2385/4885SIRT2 3154/4885MAPKAPK2 1349/4885 |
| US-20050054634-A1 | Modulating active of receptors; therapy prevention of disease such aas symthrome X, antidiabetic agents, insulin resistance, hypoglycemic agents | GPR119, IRS1, INSR | SIRT1 736/4885SIRT2 1486/4885MAPKAPK2 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.